ERBB2 and breast carcinoma: The standard adjuvant treatment ERBB2 (formerly HER2 or HER2/neu)-positive breast cancer includes chemotherapy and 1 year of trastuzumab, a recombinant, humanized monoclonal antibody that targets the ERBB2 receptor.